Bellevue Life Sciences Acquisition CORP 8-K filings

Bellevue Life Sciences Acquisition Corp. (BLAC) has completed its business combination with OSR Holdings Co., Ltd., changing its name to OSR Holdings, Inc., and anticipates its stock and warrants will begin trading on the Nasdaq under the symbols OSRH and OSRHW on February 18, 2025.

Bellevue Life Sciences Acquisition Corp. amended its promissory notes with Bellevue Global Life Sciences Investors, LLC, extending the maturity date to September 30, 2025, regardless of whether a business combination is completed.

Bellevue Life Sciences Acquisition Corp. amends promissory notes with its sponsor, Bellevue Global Life Sciences Investors, LLC, extending the maturity date to the earlier of September 30, 2025, or the consummation of an initial business combination.

Bellevue Life Sciences Acquisition Corp. has amended its business combination agreement with OSR Holdings and its PIPE subscription agreement with Toonon Partners, modifying terms related to redemption features and put/call rights.

Bellevue Life Sciences Acquisition Corp. has successfully extended its deadline to complete a business combination to February 14, 2025, and removed a net tangible asset requirement, following a shareholder vote on November 12, 2024.

Bellevue Life Sciences Acquisition Corp. has provided a $300,000 loan to OSR Holdings, bearing a 3.96% interest rate, as part of their ongoing business combination agreement.

Bellevue Life Sciences Acquisition Corp. has entered into an agreement for an $800,000 loan that may convert to equity upon a future financing event.

Bellevue Life Sciences Acquisition Corp. issued a $40,000 promissory note to a board member and extended its business combination deadline with a $50,000 deposit into its trust account.

Bellevue Life Sciences Acquisition Corp. has entered into a subscription agreement with Toonon Partners Co., Ltd. for a $20 million private investment in public equity (PIPE) transaction.

Bellevue Life Sciences Acquisition Corp. has been granted an extension by Nasdaq to regain compliance with listing rules, with a deadline of February 17, 2025.

Bellevue Life Sciences Acquisition Corp. has amended promissory notes with Jun Chul Whang and Josh Pan, extending their maturity dates to the earlier of March 31, 2025, or the completion of a business combination.

Bellevue Life Sciences Acquisition Corp. deposited $50,000 into a trust account to extend the deadline for completing a business combination.

Bellevue Life Sciences Acquisition Corp. has received a second notice from Nasdaq for not meeting the minimum public holder requirement and intends to request a hearing to avoid delisting.

Bellevue Life Sciences Acquisition Corp. deposited $50,000 into a trust account to extend the deadline for completing a business combination.

Bellevue Life Sciences Acquisition Corp. received a $300,000 unsecured loan from its sponsor, Bellevue Global Life Sciences Investors, LLC, to extend the deadline for completing a business combination.

Bellevue Life Sciences Acquisition Corp. has appointed Sang Hyun Kim to its Board of Directors, filling vacancies on the Audit, Compensation, and M&A Committees.

Bellevue Life Sciences Acquisition Corp. reported the resignation of two board members, leading to non-compliance with Nasdaq listing rules regarding board independence and committee composition.

Bellevue Life Sciences Acquisition Corp. and OSR Holdings Co., Ltd. have amended their business combination agreement, reducing the aggregate consideration and updating board designations.

Bellevue Life Sciences Acquisition Corp. has extended its deadline to complete a business combination to November 14, 2024, and secured a $140,000 promissory note from its sponsor.

Bellevue Life Sciences Acquisition Corp. is urging stockholders to vote in favor of an extension to complete its merger with OSR Holdings at a reconvened meeting on May 14, 2024.

Bellevue Life Sciences Acquisition Corp. adjourned its special stockholder meeting on May 10th without conducting any business and rescheduled it for May 14th, allowing shareholders to withdraw redemption requests.

Bellevue Life Sciences Acquisition Corp. has obtained a $50,000 loan from its sponsor and received an extension from Nasdaq to regain compliance with listing requirements.

Bellevue Life Sciences Acquisition Corp. has obtained a $1.2 million promissory note from its sponsor, Bellevue Global Life Sciences Investors LLC, to support operations.

Bellevue Life Sciences Acquisition Corp. has issued a $60,000 promissory note to Josh Pan, a member of its sponsor, with repayment contingent on a business combination or a specified date.

Bellevue Life Sciences Acquisition Corp. received a notice from Nasdaq stating they no longer meet the minimum public holder requirement and have until April 1, 2024, to submit a plan to regain compliance.

Bellevue Life Sciences Acquisition Corp. issued a $75,000 promissory note to a board member and extended its deadline to complete a business combination.